PROVIDER PROFILE · NPI 1790950863

Alexander LesokhinM.D.

PRACTICEMSKCCSee all providers at this practice →

Hematology-OncologyNew York, NYI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

400

Unique beneficiaries

—

Total services

900

Distinct HCPCS

Medicare payment

$87K

Peer benchmark

Total Medicare services vs. 628 Hematology-Oncology providers in NY — above median (cohort median 883).

PRESCRIBING · PART D · 2024

Total Rx claims

922

Beneficiaries

—

Total drug cost

$3.3M

Distinct drugs

Brand share

30.0%

Top prescribed drugs

Acyclovir196 claims

Lenalidomide89 claims

Omeprazole71 claims

Sulfamethoxazole/Trimethoprim69 claims

Rivaroxaban57 claims

QUALITY · MIPS · 2024

Final MIPS score

82.9

Quality

80.3

Cost

62.3

Improvement activities

40.0

Promoting interop.

0.0

Payment adjustment

0.33%

Group

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$15K

Payment records

By payment type

Consulting Fee$14K

Food and Beverage$306

REFERRAL NETWORK

Where Alexander Lesokhin's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 5 inbound referrers · 0 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
Dean Carlow Pathology · New York, NY	50	310
Michael Baum Cardiology · New York, NY	13	38
Hani Hassoun Hematology-Oncology · New York, NY	13	88
April Chiu Pathology · Rochester, MN	12	87
Howard Weinstein Cardiology · New York, NY	12	37

Refers patients to

Outbound — where patients go next

No outbound pairs above the suppression threshold.

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history